Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381478 | 0.88 | THRB (0.52) | SMN1; SMN2MAPTTSHRKDM4EMEN1 | |
| SCHEMBL20379417 | 0.88 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTTSHRKDM4EMEN1 | |
| SCHEMBL21381476 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTTSHRKDM4EMEN1 | |
| SCHEMBL20379410 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTTSHRKDM4EMEN1 | |
| SCHEMBL20379084 | 0.85 | MAPT (0.47) | SMN1; SMN2MAPTTSHRKDM4EMEN1 | |
| SCHEMBL28331433 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTTSHRKDM4EMEN1 | |
| SCHEMBL21381473 | 0.83 | TRPV6 (0.46) | SMN1; SMN2MAPTTSHRKDM4EMEN1 | |
| SCHEMBL21373641 | 0.79 | PTGS2 (0.41) | MAPTKDM4EMEN1KMT2ACMA1 | |
| SCHEMBL21381467 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2TSHRKMT2ALMNATP53 | |
| SCHEMBL21373504 | 0.77 | TSHR (0.56) | SMN1; SMN2MAPTTSHRKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768673-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2021-01-27 | — | — | EP | claimed |
| WO-2019179890-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2019-09-26 | — | — | WO | claimed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | claimed |
| EP-3568133-B1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH ZUERICH (CH) | 2023-12-13 | — | — | EP | disclosed |
| CN-116462666-A | Cytoprotective compounds and uses thereof | 瑞士苏黎世联邦理工学院 | 2023-07-21 | — | — | CN | disclosed |
| US-11628159-B2 | Cell-protective compounds and their use | ETH ZURICH (CH) | 2023-04-18 | — | — | US | disclosed |
| EP-3768673-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2021-01-21 | — | — | US | disclosed |
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH Zürich (CH) | 2019-11-14 | — | — | US | disclosed |
| WO-2019179890-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2019-09-26 | — | — | WO | disclosed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343802-A1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | SRPK2, SRSF2, SRPK1 | SMN1; SMN2 1351/4885MAPT 4699/4885TSHR 4051/4885 |
| US-20210015793-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | PPT1, SPTLC1, LPCAT1 | SMN1; SMN2 107/4885MAPT 91/4885TSHR 4321/4885 |
| US-11628159-B2 | Cell-protective compounds and their use | SRPK2, SRSF2, SRPK1 | SMN1; SMN2 1351/4885MAPT 4699/4885TSHR 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.